We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lorus Therapeutics Announces a Scientific Publication on Therapeutic siRNA in Cancer Therapy
News

Lorus Therapeutics Announces a Scientific Publication on Therapeutic siRNA in Cancer Therapy

Lorus Therapeutics Announces a Scientific Publication on Therapeutic siRNA in Cancer Therapy
News

Lorus Therapeutics Announces a Scientific Publication on Therapeutic siRNA in Cancer Therapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lorus Therapeutics Announces a Scientific Publication on Therapeutic siRNA in Cancer Therapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lorus Therapeutics Inc. has announced publication of scientific data from preclinical studies demonstrating the antitumor activity of its lead small interfering RNA (siRNA) candidate, siRNA-1284.

The article titled "RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo" is published online in the peer-reviewed journal Anti-Cancer Drugs and will appear in print in the April issue.

The paper presents data indicating that siRNA-1284 significantly decreases the expression of the R2 subunit of ribonucleotide reductase in a range of human tumor cell lines in vitro.

Lorus' research demonstrates that down-regulation of R2 led to a significant decrease in tumor cell growth and subsequent cell cycle inhibition in vitro.

siRNA-1284 also demonstrated potent antitumor activity in vivo in xenograft models of human cancers including renal cell carcinoma, melanoma and colon adenocarcinoma. This article marks Lorus' first major publication of detailed scientific findings for research in the area of RNA interference and siRNA technology.

"We are pleased with the publication of these data in Anti-Cancer Drugs and see it as further validation of Lorus' progress in translating RNA interference science into clinically relevant therapeutics," said Dr. Aiping Young, Lorus' President and CEO.

"Gene silencing by RNA interference is a valuable tool in gene function studies and a novel therapeutic approach to drug development. The results presented in this publication further validate R2 as an important antitumor target," Young added.

Advertisement